A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 5433-5438

  Jung, Jin Ah ^a   Kim, Tae Eun ^b   Lee, Hyun ^c   Jeong, Byeong Ho ^c   Park, Hye Yun ^c   Jeon, Kyeongman ^c   Jung Kwon, O ^c   Ko, Jae Wook ^d   Choi, Rihwa ^e   Woo, Hye In ^e   Koh, Won Jung ^c   Lee, Soo Youn ^d,e  

^a Inje University College of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Department of Clinical Pharmacology and Therapeutics ^*  (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

INH regimen; NAT2 genotype; Pharmacogenomics; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ARYLAMINE ACETYLTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; NAT2 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT;

ADULT; AGE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PHARMACOGENETICS; PILOT STUDY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SEQUENCE ANALYSIS; SEX DIFFERENCE; SOUTH KOREA; TANDEM MASS SPECTROMETRY; TOXIC HEPATITIS; TUBERCULOSIS; AGED; ALGORITHM; BIOLOGICAL MODEL; BLOOD; DOSE CALCULATION; DRUG MONITORING; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERSONALIZED MEDICINE; PHENOTYPE; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BODY WEIGHT; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; GENOTYPE; HUMANS; ISONIAZID; LINEAR MODELS; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; PHENOTYPE; PRECISION MEDICINE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84943188575     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S87131     Document Type: Article

References (22)

1. World Health Organization Global Health Observatory. Tuberculosis. Available from: http://www.who.int/gho/tb/en/index.html. Accessed February 21, 2015.
2. World Health Organization. Guidelines for Treatment of Tuberculosis. Available from: http://www.who.int/tb/publications/2010/9789241547833/en/. Accessed February 23, 2015.
3. Joint Committee for the Development of Korean Guidelines for TB and Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis. 2014.
4. Du H, Chen X, Fang Y, et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep. 2013;40(5):3591-3596.
5. Wang JY, Liu CH, Hu FC, et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62(6):448-455.
6. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol. 2011;26(2):312-318.
7. Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997;155(5):1717-1722.
8. Donald PR, Sirgel FA, Venter A, et al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis. 2004;39(10):1425-1430.
9. Lee SY, Lee KA, Ki CS, et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem. 2002; 48(5):775-777.
10. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272-276.
11. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323-1330.
12. Kayhan S, Akgüneş A. Therapeutic monitoring of isoniazid, rifampicin, ethambutol and pyrazinamide serum levels in the treatment of active pulmonary tuberculosis and determinants of their serum concentrations. Afr J Pharm Pharmacol. 2011;5(17):2015-2041.
13. Van Tongeren L, Nolan S, Cook VJ, FitzGerald JM, Johnston JC. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis. 2013;17(2):221-224.
14. Um SW, Lee SW, Kwon SY, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis. 2007;11(9):972-978.
15. Zabost A, Brzezińska S, Kozińska M, et al. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in polish tuberculosis patients. Biomed Res Int. 2013;2013:853602.
16. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49(5):1733-1738.
17. Azuma J, Ohno M, Kubota R, et al; Pharmacogenetics-based tuberculosis therapy research group. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013; 69(5):1091-1101.
18. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169-2183.
19. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839-854.
20. Babalik A, Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J. 2011;18(4):225-229.
21. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995;57(3):581-592.
22. Sunahara S, Uranom, Ogawam. Genetical and geographic studies on isoniazid inactivation. Science. 1961;134(3489):1530-1531.